Vulvovaginal candidiasis in Mato Grosso, Brazil: pregnancy status, causative species and drugs tests

Dias, Luciana Basili; Melhem, Márcia de Souza Carvalho; Szeszs, Maria Walderez; Filho, José Meirelles; Hahn, Rosane Christine

doi:10.1590/s1517-83822011000400009

Cited by 24 publications

(30 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies show that 70–75% of all women of reproductive age develop at least one case of VVC during their lifetime 6, 7. The recurrence rate is 40–50%, and approximately 5–8% develop recurrent vulvovaginal candidiasis (RVVC), which is characterized by four or more episodes of disease over a period of twelve months 6, 7, 8…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Candida spp. in cervical-vaginal samples and the in vitro susceptibility of isolates

Brandolt

Klafke

Gonçalves

et al. 2017

Brazilian Journal of Microbiology

View full text Add to dashboard Cite

Vulvovaginal candidiasis (VVC) is an infection of the genital mucosa caused by different species of the genus Candida. Considering the lack of data on this topic in the south of Brazil, this study aimed to assess the prevalence of Candida spp. in the cervical-vaginal mucosa of patients treated at a university hospital in southern Rio Grande do Sul, as well as the etiology and the susceptibility of the isolates against fluconazole, itraconazole, miconazole and nystatin. Samples were collected at the gynecology clinic of the Federal Hospital of the University of Rio Grande, and the isolates were identified using phenotypic and biochemical tests. The susceptibility analysis was performed according to the CLSI M27-A2 protocol. Of the 263 patients included, Candida spp. was isolated in 27%, corresponding to a prevalence of approximately 15% for both VVC and colonization. More than 60% of the isolates were identified as Candida albicans; C. non-albicans was isolated at a rate of 8.6% in symptomatic patients and 14.3% in asymptomatic patients. The prevalence of resistance against fluconazole and itraconazole was 42% and 48%, respectively; the minimal inhibitory concentration of miconazole ranged from 0.031 to 8 μg/mL, and that of nystatin ranged from 2 to >16 μg/mL. The high rate of resistance to triazoles observed in our study suggests the necessity of the association of laboratory exams to clinical diagnosis to minimize the practice of empirical treatments that can contribute to the development of resistance in the isolates.

show abstract

Section: Introductionmentioning

confidence: 99%

“…The recurrence rate is 40–50%, and approximately 5–8% develop recurrent vulvovaginal candidiasis (RVVC), which is characterized by four or more episodes of disease over a period of twelve months 6, 7, 8…”

Section: Introductionmentioning

confidence: 99%

Prevalence of Candida spp. in cervical-vaginal samples and the in vitro susceptibility of isolates

Brandolt

Klafke

Gonçalves

et al. 2017

Brazilian Journal of Microbiology

View full text Add to dashboard Cite

show abstract

“…17 Besides, C. albicans is reported as the most dominant species in many studies. 10,16,18,19 This difference in outcome is thought to be due to the fact that the incidence of Candida species varies according to the characteristics of the study group and the geographical region. 20 Because the variation of Candida species differs according to the geographical situation, it is thought that such studies should be repeated in different regions.…”

Section: Discussionmentioning

confidence: 99%

Antifungal susceptibilities and identification of Candida species by using maldi-tof microbial identification system from cervicovaginal samples

Erbaş¹,

Parın²,

Kırkan³

et al. 2017

Int J Res Med Sci

View full text Add to dashboard Cite

Background: Among the vaginal diseases seen in women, candidiasis is in the first place. This disease, which is caused by Candida species, can sometimes persist very stubbornly. The aim of this study was to determine Candida species isolated from vaginal specimens by using VITEK MS (MALDI-TOF Microbial Identification System) rapid identification system and to evaluate their susceptibility to some antifungals.Methods: In this study, 220 cervicovaginal swab were used. Isolates were identified by VITEK MS rapid identification system. After identification, antifungal susceptibility testing was performed using the M-44 A2 guideline of The Clinical and Laboratory Standards Institute (CLSI).Results: Total 16.3% (36) of Candida spp. positivity was determined from 220 cervicovaginal samples, and 25 (69.4%) C. glabrata, 6 (16.7%) C. albicans, 3 (8.3%) C. kefyr and 2 (5.6%) C. krusei were obtained with Vitek MS. All identified C. albicans strains were found to be completely resistant to all antifungals used except nystatin agent, C. krusei strains were found to be resistant to flucytosine but sensitive to all other antifungals, C. glabrata and C. kefyr strains were susceptible to all antifungals within the antifungals used in this study.Conclusions: It is concluded that it is necessary to distinguish Candida species in order to apply a correct treatment. And species selection is very important for the selection of antifungal to be used. Nystatin is recommended if no laboratory tests are to be performed for the diagnosis of Vaginal Candidiasis.

show abstract

“…Candida spp. se puede aislar del tracto vaginal en 20 a 30% de las mujeres no embarazadas asintomáticas saludables, en un solo punto en el tiempo y en hasta el 70% si se realiza el seguimiento longitudinal por un periodo de un año [6,14,35,[40][41][42][43].…”

Section: Etiología De Las Vulvovaginitis Por Candida (Vvc)unclassified

“…Se considera que en el embarazo la prevalencia de Candida aumenta de acuerdo a las semanas de gestación y tiene su pico en el tercer trimestre [42][43]. La candidosis vulvovaginal se ha asociado con un aumento en el riesgo de corioamnioitis en el embarazo, con el síndrome de vestibulitis de vulva y parto prematuro [14,[40][41][42][43].…”

Section: Etiología De Las Vulvovaginitis Por Candida (Vvc)unclassified

Candidosis vaginal. Segunda parte:diagnóstico, tratamiento y situación de algunos países latinoamericanos

Uribarren-Berrueta

Pineda-Murillo

Cortés-Figueroa

et al. 2017

Rev. Médica Risaralda

View full text Add to dashboard Cite

Las levaduras del género Candida causan enfermedades en los humanos que abarcan desde infecciones superficiales no graves, hasta sistémicas y potencialmente mortales. La candidiasis o candidosis, es el origen común de enfermedad vaginal y aunque es una infección no considerada como incapacitante, suele causar síntomas molestos que alteran la conducta del paciente. En México se considera la única micosis de reporte obligatorio ante las autoridades sanitarias. Por lo anterior, en este trabajo se efectuó una revisión bibliográfica para conocer el estado del arte de la vulvovaginitis causada por Candida spp. (VVC), y ofrecer una breve descripción acerca de la frecuencia presentada por esta infección en diversos países de Latinoamérica, con especial énfasis en México. Se muestra que las frecuencias de VVC en Latinoamérica, son muy parecidas a las reportadas en países como Estados Unidos de América; asimismo, Candida albicans sigue prevaleciendo como el principal agente etiológico. Las diferencias encontradas entre países desarrollados con respecto a los latinoamericanos, consisten básicamente en los métodos diagnósticos y el tipo de tratamiento. Desafortunadamente, en México, a pesar de que la VVC ocupa el noveno lugar entre las 20 principales causas de enfermedad del país, en muy pocos casos se efectúa la identificación de la especie causante, lo que constituye un dato de importancia epidemiológica, considerado como la base para investigar los factores que aumentan el riesgo de contagio, en especial por especies Candida no-albicans y para determinar si la enfermedad es prevenible o controlable.

show abstract

Vulvovaginal candidiasis in Mato Grosso, Brazil: pregnancy status, causative species and drugs tests

Cited by 24 publications

References 19 publications

Prevalence of Candida spp. in cervical-vaginal samples and the in vitro susceptibility of isolates

Prevalence of Candida spp. in cervical-vaginal samples and the in vitro susceptibility of isolates

Antifungal susceptibilities and identification of Candida species by using maldi-tof microbial identification system from cervicovaginal samples

Candidosis vaginal. Segunda parte:diagnóstico, tratamiento y situación de algunos países latinoamericanos

Contact Info

Product

Resources

About